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Introduction
Organic molecules synthesized by plants constitute a rich re-
servoir of biologically active compounds. For centuries extracts
from various plants have been extensively used in traditional
medicines for the treatment of a wide variety of human ail-
ments; even today, many cultures still employ them directly
for medicinal proposes.
[1–4] Among the classes of recognized
therapeutically useful products, pentacyclic triterpeniods have
been studied intensively for their diverse biological, pharmaco-
logical, and medicinal activities, which are similar to those of
retinoids and steroids.
[5,6] However, these triterpeniods exhibit
only weak effects on the biological activity of their molecular
targets; therefore these compounds have been used as build-
ing blocks for the synthesis of more active analogues.
[6]
Oleanolic acid, an abundantly occurring triterpene, has been
converted into 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid
(CDDO) and other structurally related analogues (CDDO-Me,
CDDO-Im, CDDO-CN; Scheme 1A).
[7–9] All of these synthetic de-
rivatives were reported to display various bioactivities: cyto-
protection, cancer cell growth inhibition, apoptosis induction,
and inhibition of the production of NO induced by INF-g in
mouse macrophages.
[7–12] CDDO and CDDO-Me are currently in
clinical trials for cancer treatment, and have been shown to ef-
fectively suppress the growth of a broad spectrum of solid and
hematologic cancer cell types, both in vitro and in mouse
models bearing xenografted human tumors.
[9–12] During the de-
velopment of CDDO, it was found that the 2-cyano-1-en-3-one
in ring A, and the 9(11)-en-12-one in ring C are essential for
the biological activity of CDDO and its analogues.
[13–15]
18bH-Glycyrrhetinic acid (Scheme 1B), the aglycon of glycyr-
rhizin, is abundant in licorice root (Glycyrrhiza glabra and Gly-
cyrrhiza uralensis Fischer). The glycyrrhizin content in triterpene
extracts from licorice root amounts to 90%. Recent reviews
have described the wide spectrum of glycyrrhetinic acid bio-
activity, such as anti-inflammatory, antiviral, hepatoprotective,
antitumor, and immunomodulatory activities.
[16,17] Several stud-
ies have reported that glycyrrhizin and glycyrrhetinic acid have
moderate cytotoxic and apoptotic effects on cancer cells, al-
though most reported only moderate or low potency.
Triterpenoids are used for medicinal purposes in many coun-
tries. Some, such as oleanolic and glycyrrhetinic acids, are
known to be anti-inflammatory and anticarcinogenic. However,
the biological activities of these naturally occurring molecules
against their particular targets are weak, so the synthesis of
new synthetic analogues with enhanced potency is needed. By
combining modifications to both the A and C rings of 18bH-
glycyrrhetinic acid, the novel synthetic derivative methyl 2-
cyano-3,12-dioxo-18bH-olean-9(11),1(2)-dien-30-oate was ob-
tained. This derivative displays high antiproliferative activity in
cancer cells, including a cell line with a multidrug-resistance
phenotype. It causes cell death by inducing the intrinsic cas-
pase-dependent apoptotic pathway.
Scheme 1. A) Structure of CDDO and its structurally related analogues.
B) Structure of glycyrrhetinic acid.
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tinic acid, we synthesized compounds 2–12, similar to CDDO-
Me (1), by introducing modification at both rings A and C
(Scheme 1A). We investigated the effects of the novel deriva-
tives on the growth of human cancer cells, and we identified
methyl 2-cyano-3,12-dioxo-18bH-olean-9(11),1(2)-dien-30-oate
12 as a compound displaying significant antiproliferative activi-
ty toward cancer cells; the other glycyrrhetinic-acid derivatives
did not display this activity. We compared 12 and CDDO-Me
on several cell lines under the same conditions, and we
showed that IC50 was lower for 12 than CDDO-Me for all cell
lines. Compound 12 induced cell-cycle arrest, the translocation
of phosphatidylserine to the cell surface, and fragmentation of
the nucleus. It also caused a dramatic dissipation of the mito-
chondrial potential, and induced activation of the caspase cas-
cade; these effects were more pronounced for 12 than for
CDDO-Me. The data indicate that 12 induces the death of
cancer cells by the intrinsic caspase-dependent apoptosis path-
way.
Results and Discussion
Chemical synthesis
The reaction sequence to intro-
duce the 2-cyano-1-en-3-one
and 9(11)-en-12-one in A and C
rings of glycyrrhetinic acid is
shown in Scheme 2.
18bH-Glycyrrhetinic acid ace-
tate 2, obtained from a licorice
extract, was used as the starting
material. Compound 2 was es-
terified at 08C with ethereal di-
azomethane to give methyl gly-
cyrrhetinate acetate 3, which
was reduced by Zn/HCl in di-
oxane at 5–108C. The resulting
methyl ester of 11-deoxoglycyr-
rhetinic acid acetate 4 was con-
verted into 12-oxo derivative 5
by treating with hydrogen per-
oxide in acetic acid at 808C. The
formation of the 9,11-double
bond was achieved by bromina-
tion–dehydrobromination of
ketone 5 with bromine in acetic
acid at 808C. Finally the 9(11)-
en-12-one moiety in the C ring
was obtained. Deprotection of
acetate group by KOH in metha-
nol (reflux) freed the 3-hydroxy
group, then Jones oxidation
gave the ketone 8. Subsequent
formylation at C
2 was performed
by condensation with HCO2Et/
NaOMe in benzene, and the re-
sulting hydroxymethylene derivative 9 was cyclized into isoxa-
zole 10 by reacting with hydroxylamine hydrochloride in aque-
ous ethanol (reflux). Opening of the isoxazole ring at the NO
bond was promoted by NaOMe routinely to deliver the 2-
cyano group in 11. The new 1,2 double bond was formed by
dehydrogenation with 2,3-dichloro-5,6-dicyano-1,4-benzoqui-
none (DDQ) in benzene (reflux) to complete the synthesis of
the 2-cyano-1-en-3-one moiety in A ring in 12.
It should be noted that the synthesis scheme for our end-
product 12 has been described by Chadalapaka et al.
[18] Our in-
vestigations were conducted independently and in parallel. In
addition to the synthesis scheme, a detailed description of the
synthesis and physicochemical properties of the end product
(and of the intermediates) is presented in this work (see the
Experimental Section).
Biological studies
Cell-viability inhibition: Inhibitors of cell growth are potentially
useful as chemopreventive and chemotherapeutic agents. The
Scheme 2. Synthesis of methyl 2-cyano-3,12-dioxo-18bH-olean-9(11),1(2)-dien-30-oate (12). a) CH2N2, MeOH-Et2O
(08C to RT), 89%; b) Zn (powder), HCl (conc.), dioxane (5–108C), 77%; c) H2O2, AcOH (808C), 96%; d) Br2, AcOH
(808C), 75%; e) KOH, MeOH (reflux), 90%; f) Jones reagent, acetone (RT), 94%; g) HCOOEt, NaOMe, benzene (RT),
95%; h) NH2OH·HCl, EtOH-H2O (reflux), 73%; i) NaOMe, MeOH-Et2O( 08C to RT), 100%; j) 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (DDQ), benzene (reflux), 61%.
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Glycyrrhetinic Acid Derivativesin vitro cytotoxicity of the novel derivatives of glycyrrhetinic
acid against human epidermoid cancer cell-line KB-3-1 was de-
termined by using the MTT assay, a colorimetric technique for
the determination of cell viability which was developed for the
initial stages of drug screening, The assay quantifies the reduc-
tion of the yellow tetrazole 3-(4,5-Dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) to its purple formazan deriv-
ative by mitochondrial dehydrogenase. It assumes cell viability
to be proportional to the production of formazan, and thus
low IC50 values imply high cytotoxicity or antiproliferation ac-
tivity.
Glycyrrhetinic acid, 7, 8, 9, 10 and 12 were tested; the other
derivatives were found to be insoluble in dimethylsulfoxide
(DMSO). Cells were exposed to the compounds for 24 h and
then assayed for growth by the MTT method. The cells were
also incubated in the presence of CDDO-Me 1, whose ability to
inhibit cancer-cell growth was established earlier (reviewed by
Liby et al.).
[19] Figure 1 shows the dose–response curves for 1
and 12 with KB-3-1 cells, and the IC50 values for all the tested
compounds (for the inhibition of KB-3-1 cell growth) are pre-
sented in Table 1. Compound 12 displayed the highest activity.
The in vitro IC50 values (the concentrations required for 50%
growth inhibition) were 0.3 and 1.2 mm for 12 and 1, respec-
tively (Table 1). IC50 values for the other glycyrrhetinic acid de-
rivatives were greater than 10 mm.
We compared the effects of 12 and 1 on the growth of dif-
ferent human cancer cell-lines: KB-3-1 epidermoid carcinoma
cells, KB-8-5 multidrug-resistant cancer cells (a derivative of KB-
3-1), HeLa cervical epithelioid carcinoma cells, MCF-7 breast
adenocarcinoma cells, and SKNMC neuroblastoma cells. The
dose–response curves for 12 with the different cell lines are
displayed in Figure 2. Compound 12 induces concentration-de-
pendent cell death in all cell lines tested. IC50 values for 12 and
1 are displayed in Table 2. The IC50 values for compounds were
similar for all cell lines, with the exception of MCF-7, for which
IC50 was more that ten times higher than for KB-3-1 (5 mm vs
0.3 mm for 12). IC50 values for 12 were lower than for 1 for all
tested cell lines.
One of the reasons for the failure of chemotherapy-based
treatment is multidrug resistance (MDR). We tested the ability
of 12 to suppress the growth of multidrug-resistant KB-8-5
cells. This cell line is characterized by overexpression of the
MDR1 gene, which encodes P-glycoprotein, an ATP-dependent
membrane pump that efficiently decreases the intracellular
concentrations of various compounds. Treatment of KB-8-5
cells with 12 significantly decreased the number of living cells
(Figure 2); the IC50 value for this cell line was only four times
higher than the IC50 for the drug-sensitive KB-3-1 (0.3 mm for
KB-3-1 vs 1.2 mm for KB-8-5). Thus, this glycyrrhetinic acid deriv-
ative is not targeted at P-glycoprotein, and might be efficient
against tumors exhibiting the P-glycoprotein-dependent MDR
phenotype.
Figure 1. Effects of 1 and 12 on the viability of KB-3-1 cells. Cells were incu-
bated for 24 h in the presence of 1 and 12 (0.1, 5 and 10 mm). Cell viability
was measured by MTTassay as described in the Experimental Section. The
results are expressed as percentages of viable cells observed after treatment
with compounds relative to control cells (100%) incubated in the presence
of DMSO (0.1% (v/v)). The data were obtained from three separate experi-
ments in triplicate.
Table 1. IC50 values of glycyrrhetinic acid, its derivatives 1, 7, 8, 9, 10,
12.
[a]
Compounds IC50 [mm] Compounds IC50 [mm]
glycyrrhetinic >10 8 >10
acid 9 >10
1 1.20.16 10 >10
7 >10 12 0.30.08
[a] IC50 was defined as the compound concentration that resulted in 50%
KB-3-1 cell survival as measured by the MTT assay (see Experimental Sec-
tion). Incubation time: 24 h.
Figure 2. Dose–response curves for 12 with different human cancer cell
lines. Cells were incubated for 24 h with increasing concentrations of 12 (0.1
to 100 mm). Cell viability was measured by the MTTassay as described in the
Experimental Section. The results are expressed as percentages of viable
cells observed after treatment, relative to control cells (100%) incubated in
the presence of DMSO (0.1% (v/v)). Data were obtained from three separate
experiments in triplicate.
Table 2. IC50 values for 12 and oleanolic acid derivative 1 with human
cancer cell lines.
[a]
Cell line 12 1
KB-3-1 0.30.08 1.20.16
KB-8-5 1.20.12 3.10.29
HeLa 1.30.28 2.80.37
MCF-7 50.34 >10
SK-N-MC 0.80.1 4.90.6
[a] IC50 was defined as the compound concentration that resulted in
50% cell survival as measured by the MTT assay (see Experimental Sec-
tion). Incubation time: 24 h.
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to CDDO and many other synthetic triterpenoids, 12 has po-
tential electrophilic Michael acceptor sites at positions 1 and 9
of the triterpenoid nucleus (Figure 3A). It is known that the
presence of Michael acceptor groups at specific positions is es-
sential for inhibition of proliferation, promotion of differentia-
tion, and induction of apoptosis in various cell lines. This arises
from the ability of Michael electrophiles to target specific nu-
cleophiles, and to affect selective biological functions.
[20–22] The
involvement of the Michael electrophiles in a particular biologi-
cal process can be proved by inhibition of their activity with
antioxidants, for example glutathione (GSH).
We investigated whether reducing the nucleophilic agents
would abrogate the cytotoxicity of 12. Cells were incubated in
the presence of GSH (1, 5, 15 or 45 mm), either alone or in
combination with 12 (1 mm; Figure 3B). Incubation of cells in
the presence of 12 with of GSH (5 or 15 mm) decreased the
cytotoxicity of 12. The IC50 value in the presence of GSH was
3 mm, but only 0.3 mm for 12 alone. Higher concentrations of
GSH were toxic: incubation in the presence of 45 mm gluta-
thione led to 95% cell death (data not shown). It should be
noted that incubation with ascorbic acid did not decrease the
cytotoxicity of compound 12 (not shown). Thus, we demon-
strated that 12 displays biologically active Michael acceptors.
Cell-cycle arrest: Flow cytometry was employed to determine
whether 12 caused stage-specific inhibition of the cell cycle
(Table 3). After 18 h incubation in the absence of 12, the
number of cells with sub-G1 (apoptotic) peak was insignificant.
An increase in the concentration of 12 (0.3 to 1 mm ) yielded a
corresponding increase in the population of cells in sub-G1
(19.2 to 51.8% ; values relative to the control) in a concentra-
tion-dependent manner (n=3; p<0.05). The increase in the
population of cells in the sub-G1 phase was accompanied by a
decrease of cells in the G1 and S phases (Table 3). It has been
reported that cells with these features are those dying of
apoptosis.
[23] The number of cells in the G2-M phase remained
constant.
Morphological observation of nuclear change: There are sev-
eral morphological characteristics for apoptotic cells, such as
cell shrinkage, nuclear fragmentation and chromatin condensa-
tion. To examine cell death due to exposure to 12, we investi-
gated the nuclear morphological changes in KB-3-1 cells treat-
ed with 1 mm 12 for 6, 18 and 24 h (Figure 4). Nuclear staining
with Hoechst 33258 demonstrated that control KB-3-1 cells
had regular and round-shaped nuclei (Figure 4A). In contrast,
condensation and fragmentation of nuclei, characteristic of
apoptotic cells, were observed in cells treated with 12. After
6 h exposure, patches of localized partially condensed chroma-
tin were found on the inner face of the nuclear membrane
(Figure 4B), while the nuclei appeared slightly deformed. The
number of such nuclei dramatically increased up to 18 h (Fig-
Figure 3. GSH treatment abrogates the cytotoxicity of 12 in KB-3-1 cells.
A) Activation of the Michael acceptor sites at positions 1 and 9 of com-
pound 12. B) Effect of GSH on viability of KB-3-1 cells. Cells were treated for
24 h with the indicated concentrations of either GSH alone (&), or in combi-
nation with 1 mm 12 (&). Cell viability was measured by the MTT assay as de-
scribed in the Experimental Section. The results are expressed as percentag-
es of viable cells observed after treatment, relative to control cells (100%)
incubated in the presence of DMSO (0.1% (v/v)). The data were obtained
from three separate experiments done in triplicate.
Table 3. Effect of 12 on the cell cycle of KB-3-1 cells.
[a]
Conc. 12 Cells in each phase of the cell cycle [%]
[mm] Sub-G1 G1 S G2/M
0 1.7 50.6 22.9 24.8
0.3 19.2 36.5 14.7 29.6
1.0 51.8 11.8 8.3 28.1
[a] KB-3-1 human epidermoid cells were seeded into six-well plates to
ensure that they had not reached confluency. After 24 h they were incu-
bated either in the absence (control) or presence of 0.3 or 1 mm 12. After
18 h the percentage of cells in each phase of the cell cycle was deter-
mined by flow cytometry as described in the Experimental Section. Data
were obtained from at least three separate experiments in duplicate.
Figure 4. Nuclear damage in KB-3-1 cells by treatment with 1 mm 12. Photos
were taken by fluorescence microscopy after nuclei staining with Hoechst
33258. The figures show the microscopic morphology of the cells incubated
in the presence of A) DMSO (0.1% (v/v), control), and in the presence of 12
for B) 6, C) 18, and D) 24 h.
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the vast majority of nuclei, with the formation of apoptotic
bodies (Figure 4D).
Quantification of apoptosis by annexin V binding and flow cy-
tometry: Increases in morphologically changed cells, and in the
number of cells in the sub-G0/G1 phase, are usually associated
with apoptosis. We examined whether cell death was apoptot-
ic when induced by the glycyrrhetinic acid derivatives by using
annexin V and propidium iodide analysis (Figure 5). KB-3-1 cells
were exposed to 12, then subjected to flow cytometric analy-
sis. Annexin V binds phosphatidylserine residues, which are
asymmetrically distributed toward the inner plasma mem-
brane, and migrate to the outer plasma membrane during
apoptosis.
[24] The data show that 12 induced apoptotic cell
death in 50% of KB-3-1 cells at concentrations equal to the
IC50 values. The number of apoptotic cells increased with the
time of incubation, and with increasing compound concentra-
tion. 89.2% of KB-3-1 cells were detected as apoptotic follow-
ing 24 h of incubation in the presence of 1 mm 12,s o12 indu-
ces dose- and time-depended apoptotic cell death. Taken
together, these data indicate that the decrease in viability of
cancer cells exposed to the novel glycyrrhetinic acid deriva-
tives occurred by apoptosis, and that 12 had the greatest
potency.
Dissipation of the mitochondrial transmembrane potential: We
investigated whether 12 utilizes the mitochondrial “intrinsic”
pathway in the apoptotic death of KB-3-1 cells, as the pivotal
role of mitochondria in the triggering of apoptosis is well es-
tablished. We evaluated the mitochondrial transmembrane po-
tential (Dym) in KB-3-1 cells exposed to 12, and compared this
to that for 1, whose ability to decrease Dym has been docu-
mented.
[10,19,25–29] Changes in Dym were evaluated by cyto-
fluorometric analysis. Cells were stained with the mitochon-
dria-specific cationic dye JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tet-
raethyl benzimidazole carbocyanine iodide), which accumu-
lates in the transmembrane region of polarized mitochondria
where it forms “J-aggregates”. These emit orange fluorescence
that can be recorded on channel 2 of a cytofluorometer, or
visualized via a red filter on a fluorescence microscope. A
decrease in Dym results in a decrease in J-aggregates and in-
crease in JC-1 monomers, which emit a greenish-yellow fluo-
rescence. The cytometric analysis of KB-3-1 cells stained with
JC-1 is shown in Figure 6B. In the control cells (incubated in
the presence of 0.1% DMSO) the majority of cells showed a
high emission of fluorescence in both channels, because of the
equilibrium between J-aggregates and monomers. The expo-
sure of KB-3-1 cells to 12 leads to a significant decrease in fluo-
rescence compared to the control (0.1% DMSO). In fluorescent
Figure 5. Quantification of apoptosis by annexin V binding to KB-3-1 cells. Cells were incubated in the presence of 0.3 or 1 mm 12, or in the presence of 0.1%
(v/v) DMSO for the indicated times. Annexin V binding was carried out with the Annexin V–FITC detection kit as described in the Experimental Section. An-
nexin V/PI staining was analyzed by flow cytometry. The lower-right quadrant of each cytometry scattergram shows the annexinV
+PI
 cells; the upper-right
quadrant shows the annexinV
+PI
+ cells. The results are representive of one of three independent experiments.
788 www.chembiochem.org   2011 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2011, 12, 784–794
E. B. Logashenko, M. A. Zenkova, et al.microscopy (Figure 6A), one can see that most of the cells turn
green. After incubation in the presence of 1, cells can be seen
to be somewhere between the control and 12-treated cells,
both in the fluorescent micrograph and in the flow-cytometry
histogram. One can conclude that 12 causes a dramatic dissi-
pation of mitochondrial potential, and that this effect, consis-
tent with the results of the MTT assay, is more pronounced
than that for 1.
Activation of the caspase cascade in apoptosis induced by gly-
cyrrhetinic acid derivatives: To determine whether activation of
the caspase cascade is involved in 12-induced apoptosis, we
used the fluorescein isothiocyanate (FITC)-labeled pan-caspase
inhibitor FITC-VAD-FMK (FITC-valyl-alanyl-aspartyl-[O-methyl]-
fluoromethylketone). The conjugated compound is cell-perme-
able and binds irreversibly to activated caspase molecules, and
thus serves as an in situ marker for apoptosis.
[30] We compared
the abilities of 12 and 1 to activate caspase (Figure 7). In con-
trol cells (18 h incubation in the presence of 0.1% DMSO) only
a faint green signal was seen: this equates to 9% of cells with
activated caspase (Figure 7A and C). With the addition of 12
(0.3 and 1 mm), the number of cells with activated caspase in-
creased (51 and 85%, respectively; Figure 7C), and green fluo-
rescence was observed in the fluorescence microscope. Similar
assays with 1 yielded data that lay between those for the con-
trol and 12, as had been the case for mitochondrial transmem-
brane potential dissipation.
The results provide evidence that the most-active glycyrrhe-
tinic-acid derivative 12 induces caspase-dependent apoptosis
in cancer cells. Caspase involvement in cell death is suggested
also by the higher IC50 for MCF-7 cells (Table 2)—cells that are
known to be caspase-3-deficient.
[31]
Conclusions
In this report we describe the synthesis of the new glycyrrhe-
tinic acid derivative methyl 2-cyano-3,12-dioxo-18bH-olean-
Figure 6. Analysis of mitochondrial transmembrane potential of KB-3-1 cells
treated with 1 and 12 by A) fluorescence microscopy, and B) flow cytometry,
following JC-1 staining. Cells were treated for 6 h with 1 or 12 (1 mm),o r
DMSO (0.1% (v/v)). In normal cells dye accumulated in mitochondria (red
fluorescence). In cells with altered mitochondrial potential dye remained as
monomers in the cytoplasm (green fluorescence). FL2=value of fluores-
cence measured on channel 2 of the cytofluorometer.
Figure 7. Induction of caspase activation in human cancer cells. A) Fluores-
cence microscopy of FITC-VAD-FMK in living KB-3-1 cells incubated for 18 h
with 0.3 mm 1 or 12. Cells were counter-stained with Hoechst dye. B) Flow
cytometry analysis of the activation of proteins of the caspase family. Cyto-
grams of FITC-VAD-FMK in living cells incubated with 1 or 12. KB-3-1 cells
without treatment (1), treated with 0.3 mm (2) and 1 mm (3) of the indicated
compounds (18 h incubation). C) Percentages of cells undergoing apoptosis
(staining positive for FITC-VAD-FMK). Percentage of cells with non-activated
(&) and activated (&) caspases after treatment with the indicated concentra-
tions of 1, 12 or DMSO (0.1% (v/v), control). Error bars indicate standard de-
viation.
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tion of the A and C rings of glycyrrhetinic acid. We provide a
detailed description of synthesis and physicochemical charac-
teristics of the end product, 12, and of the intermediate com-
pounds. The modifications converted the well-known triterpe-
noid (exhibiting weak antitumor activity) to derivative 12,
which displays high antiproliferative activity toward cancer
cells. The intermediate products 7–10 did not display this ac-
tivity.
We have shown that human epidermoid cancer cells are
sensitive to 12, as are other tumor cell types, including cells
exhibiting the multidrug-resistant phenotype. Compound 12
displays potent single-agent activity, at micromolar concentra-
tions, against different human cancer cells in culture. The
mechanism of action (MOA) of triterpenoids on cancer cells is
not fully understood. Different mechanisms have been pro-
posed for the cytotoxic activity of synthetic triterpenoids in
various types of cancer and leukemia cells; this suggests that
cellular context is important. Several studies point to an MOA
dependent on the extrinsic apoptotic pathway (DR4/DR5/cas-
pase-8 activation),
[20,32] whereas other studies point to involve-
ment of the intrinsic apoptotic pathway.
[10,33,34] Our studies
imply that the apoptotic MOA of 12 includes components of
intrinsic pathways in epidermoid cancer cells.
We have compared the ability of 12 to cause cancer-cell
death with that of CDDO-Me, a well known compound that is
currently in late-stage clinical trials for the treatment of chronic
kidney disease in type 2 diabetes mellitus patients. The anti-
proliferative activity of 12 exceeds that of CDDO-Me: the IC50
value was lower for all tested cell lines, and 12 caused a dra-
matic dissipation of mitochondrial potential and caspase-cas-
cade activation; these effects were more pronounced for 12
than for CDDO-Me. Moreover, we can suppose that commercial
synthesis of 12 will be more amenable than that of CDDO-Me
because 18bH-glycyrrhetinic acid, the starting material for the
synthesis of 12, is more readily available than oleanolic acid.
Indeed, the level of oleanolic acid in olive leaves ranges from
0.71 to 3.5%,
[35–37] and from 0.8 to 4.3% in Ligustrum fruit;
[38]
the level of glycyrrhizin can reach 25–30% in Glycyrrhiza glabra
root, and 90% in triterpene extracts of licorice root.
[39–41]
Experimental Section
Reagents: CDDO-Me 1 was synthesized from oleanolic acid accord-
ing to a previously described method
[5] with 10% yield (NMR
1H
and
13C data).
18bH-Glycyrrhetinic acid acetate 2, obtained from a licorice extract,
was used as starting material (purity~94%).
[39]
General experimental procedures: Melting points were deter-
mined on a Hoover melting point apparatus and were uncorrected.
The elemental composition of the products was determined from
high-resolution mass spectra recorded on a DFS (Double Focusing
Sector) Thermo Electron Corporation instrument.
1H and
13C NMR
spectra were measured from CDCl3 solutions on Bruker spectrome-
ters: AM-400 (400.13 MHz for
1H, 100.61 MHz for
13C) and DRX-
500 (500.13 MHz for
1H, 125.76 MHz for
13C). Chloroform was used
as the internal standard (dH 7.24 ppm, dC 76.90 ppm). The structure
of the compounds was determined by NMR from proton spin–spin
coupling constants in
1H,
1H double-resonance spectra, and by
analyzing
13C NMR proton-selective and off-resonance saturation
spectra, 2D
13C,
1H correlated spectroscopy on CH constants (COSY,
1JC,H=135 Hz; and COLOC,
2,3JC,H=10 Hz, correspondingly), and 1D
13C,
1H long-range J modulation difference (LRJMD, JC,H=10 Hz).
Flash column chromatography was performed with silica gel
(Merck, 60–200 mesh) and neutral alumina (Chemapol, 40–250
mesh).
Methyl 18bH-Glycyrrhetinate acetate (3):
[42] A solution of diazo-
methane in ether was added dropwise at 08C to a stirred suspen-
sion of 2 (10 g, 19.0 mmol) in methanol (200 mL) until the original-
ly colorless mixture turned yellow. The resulting mixture was al-
lowed to stand at room temperature overnight. The solvent was
removed and the product was purified by crystallization (chloro-
form/methanol; yield=9.1 g, 89%). M.p. 303–3048C;
1H NMR
(CDCl3): d=0.76 (dd,
3J(H
5a,H
6a)=12.5,
3J(H
5a,H
6e)=1.5 Hz; H
5a), 0.76
(s, 3H; C28-H3), 0.84 (s, 6H; C23-H3, C24-H3), 0.97 (dm,
2J(H
16e,H
16a)=13.8 Hz; H
16e), 1.01 (ddd,
2J(H
1a,H
1e)=13.5,
3J(H
1a,H
2a)=
13.5,
3J(H
1a,H
2e)=3.7 Hz; H
1a), 1.08 (s, 3H; C26-H3), 1.10 (s, 3H; C29-
H3), 1.12 (s, 3H; C25-H3), 1.14 (dm,
2J(H
15e
,H
15a)=13.8 Hz; H
15e),
1.23–1.39 (m, 4H; H
7,H
21a,2 H
22), 1.32 (s, 3H; C27-H3), 1.41 (dddd,
2J(H
6a
,H
6e)=13.5,
3J(H
6a
,H
7a)=13.5,
3J(H
6a
,H
5a)=12.0,
3J(H
6a,H
7e)=
3.2 Hz; H
6a), 1.51–1.66 (m, 3H; H
6e,H
2e,H
7’), 1.57 (dd,
2J(H
19a,H
19e)=
13.5,
3J(H
19a,H
18a)=13.5 Hz; H
19a), 1.66 (dddd,
2J(H
2a,H
2e)=13.5,
3J(H
2a,H
1a)=13.5,
3J(H
2a,H
3a)=11.7,
3J(H
2a,H
1e)=3.7 Hz; H
2a), 1.78
(ddd,
2J(H
15a,H
15e)=13.8,
3J(H
15a,H
16a)=13.8,
3J(H
15a
,H
16e)=4.5 Hz;
H
15a), 1.88 (ddd,
2J(H
19e,H
19a)=13.5,
3J(H
19e,H
18a)=4.2,
4J(H
19e,H
21e)=
2.7 Hz; H
19e), 1.95 (dm
2J(H
21e,H
21a)=10 Hz; H
21e), 1.98 (ddd,
2J(H
16a,H
16e)=13.8,
3J(H
16a,H
15a)=13.8,
3J(H
16a,H
15e)=4.8 Hz; H
16a),
2.00 (s, 3H; C33-H3), 2.04 (dd,
3J(H
18a,H
19a)=13.5,
3J(H
18a,H
19e)=
4.2 Hz; H
18a), 2.32 (s, 1H; H
9a), 2.76 (ddd
2J(H
1e,H
1a)=13.5,
3J(H
1e,H
2a)=3.7,
3J(H
1e,H
2e)=3.0 Hz; H
1e), 3.64 (s, 3H; OC31-H3), 4.47
(dd,
3J(H
3a,H
2a)=11.7,
3J(H
3a,H
2e)=4.7 Hz; H
3a), 5.62 (s, 1H; H
12);
13C NMR (CDCl3): d=38.63 (t, C1), 23.41 (t, C2), 80.45 (d, C3), 37.88
(s, C4), 54.88 (d, C5), 17.22 (t, C6), 32.55 (t, C7), 43.03 (s, C8), 61.56
(d, C9), 36.78 (s, C10), 199.85 (s, C11), 128.34 (d, C12), 169.01 (s,
C13), 45.23 (s, C14), 26.31 (t, C15), 26.26 (t, C16), 31.67 (s, C17),
48.25 (d, C18), 40.93 (t, C19), 43.87 (s, C20), 30.98 (t, C21), 37.59 (t,
C22), 27.89 (q, C23), 16.52 (q, C24), 16.24 (q, C25), 18.52 (q, C26),
23.17 (q, C27), 28.36 (q, C28), 28.15 (q, C29), 176.73 (s, C30), 51.58
(q, C31), 170.77 (s, C32), 21.13 (q, C33); HRMS: m/z calcd for
C33H50O5: 526.7471; found: 526.3658.
Methyl 3b-Acetoxy-18bH-olean-12-en-30-oate (4):
[43] A solution
of conc. hydrochloric acid (50 mL) was added dropwise at 108Ct o
a stirred suspension of 3 (9.1 g, 17.3 mmol) and zinc powder
(18.2 g, 280 mmol) in dioxane (300 mL) over 2 h. The reaction mix-
ture was stirred for a further 3 h at 5–108C, concentrated in a
vacuum, diluted with water (1 L), and filtered. The solid was dried
and subjected to flash column chromatography (silica gel; benzene
followed by chloroform) to give crude 4 (yield=6.8 g, 77%). This
material was used for the next reaction without further purifica-
tion. An analytically pure sample was obtained by recrystallization
from a mixture chloroform/methanol. M.p. 265–2678C;
1H NMR
(CDCl3): d=0.74 (s, 3H; C28-H3), 0.81 (dd,
3J(H
5a,H
6a)=12.0,
3J(H
5a,H
6e)=1.6 Hz; H
5a), 0.82–0.86 (m, H
16e), 0.83 (s, 3H; C24-H3),
0.84 (s, 3H; C23-H3), 0.93 (s, 6H; C25-H3, C26-H3), 0.94 (dm
2J(H
15e,H
15a)=13.5 Hz; H
15e), 1.02 (m; H
1), 1.09 (s, 3H; C29-H3), 1.10
(s, 3H; C27-H3), 1.17–1.35 (m, 4H; H
7,H
21,2H
22), 1.39 (m, H
6a), 1.44–
1.64 (m, 7H; H
1’,2 H
2,H
6e,H
7’,H
9a,H
19), 1.73 (ddd,
2J(H
15a,H
15e)=
13.5,
3J(H
15a,H
16a)=13.5,
3J(H
15a,H
16e) 4.6 Hz; H
15a), 1.79–1.93 (m, 5H;
2H
11,H
18,H
19’,H
21’), 1.92 (m; H
16a), 2.01 (s, 3H; C33-H3), 3.64 (s, 3H;
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E. B. Logashenko, M. A. Zenkova, et al.OC31-H3), 4.47 (dd,
3J(H
3a,H
2a)=10.0,
3J(H
3a,H
2e)=6.0 Hz; H
3a), 5.23
(t,
2J(H
12,H
11)=3.6 Hz; H
12);
13C NMR (CDCl3): d=38.13 (t, C1), 23.42
(t, C2), 80.74 (d, C3), 37.56 (s, C4), 55.13 (d, C5), 18.11 (t, C6), 32.46
(t, C7), 39.65 (s, C8), 47.42 (d, C9), 36.70 (s, C10), 23.34 (t, C11),
122.34 (d, C12), 144.23 (s, C13), 41.38 (s, C14), 25.99 (t; C15), 26.82
(t, C16), 31.79 (s, C17), 48.05 (d, C18), 42.68 (t, C19), 44.12 (s, C20),
31.15 (t, C21), 38.25 (t, C22), 27.89 (q, C23), 16.54 (q, C24), 15.41 (q,
C25), 16.64 (q, C26), 25.77 (q, C27), 28.03 (q, C28), 28.38 (q, C29),
177.46 (s, C30), 51.35 (q, C31), 170.77 (s, C32), 21.13 (q, C33);
HRMS: m/z calcd for C33H52O4: 512.7636; found: 512.3866.
Methyl 3b-acetoxy-12-oxo-18bH-olean-30-oate (5): A mixture of
hydrogen peroxide (~30%, 25 mL) and acetic acid (25 mL) was
added dropwise at 808C to a stirred suspension of 4 (3.0 g,
5.7 mmol) in acetic acid (100 mL) over 1 h. The reaction mixture
was stirred for a further 30 min at 808C, cooled to room tempera-
ture, and diluted with water (500 mL). The solid was filtered,
washed with water, and dried to give crude 5 (yield=6.8 g , 96%).
This material was used for the next reaction without further purifi-
cation. An analytically pure sample was obtained by recrystalliza-
tion from a mixture chloroform/methanol. M.p. 296–2998C;
1H NMR (CDCl3): d=0.79–0.88 (m, 2H; H
5a,H
16e), 0.82 (s, 3H; C28-
H3), 0.83 (s, 3H; C24-H3), 0.84 (s, 3H; C23-H3), 0.86 (s, 3H; C25-H3),
0.90 (s, 3H; C27-H3), 0.92–1.01 (m, 2H; H
1,H
15e), 1.09 (s, 3H; C29-
H3), 1.10 (s, 3H; C26-H3), 1.19 (dd,
2J(H
19a,H
19e)=13.4,
3J(H
19a,H
18)=
13.4 Hz; H
19a), 1.18–1.27 (m, 2H; H
21a,H
22e), 1.31–1.48 (m, 4H; 2H
7,
H
22a,H
6), 1.49–1.64 (m, 4H; H
1’,2 H
2,H
6’), 1.64 (dd
3J(H
9a,H
11a)=13.0,
3J(H
9a,H
11e)=5.1 Hz; H
9a), 1.74 (m, H
18), 1.76 (m, H
15a), 1.85 (ddd,
2J(H
16a,H
16e)=13.2,
3J(H
16a,H
15a)=13.2,
3J(H
16a,H
15e)=4.2 Hz; H
16a),
1.91 (dm,
2J(H
21e,H
21a)=13.2 Hz; H
21e), 2.00 (s, 3H; C33-H3), 2.12 (dd,
2J(H
11a,H
11e)=17.0,
3J(H
11a,H
9a)=13.0 Hz; H
11a), 2.23 (dd,
2J(H
11e,H
11a)=
17.0,
3J(H
11e,H
9a)=5.1 Hz; H
11e), 2.54 (ddd,
2J(H
19e,H
19a)=13.4,
3J(H
19e,H
18)=3.4,
4J(H
19e,H
21e)=2.8 Hz; H
19e), 2.72 (d,
3J(H
13,H
18)=
4.4 Hz; H
13), 3.68 (s, 3H; OC31-H3), 4.44 (dd,
3J(H
3a,H
2a)=11.4,
3J(H
3a,H
2e)=4.8 Hz; H
3a);
13C NMR (CDCl3): d=37.50 (t, C1), 23.26 (t,
C2), 80.28 (d, C3), 37.60 (s, C4), 55.04 (d, C5), 18.05 (t, C6), 31.63 (t,
C7), 41.41 (s, C8), 49.32 (d, C9), 36.67 (s, C10), 38.28 (t, C11), 211.91
(s, C12), 50.08 (d, C13), 41.90 (s, C14), 25.84 (t, C15), 26.29 (t, C16),
32.01 (s, C17), 38.41 (d, C18), 34.05 (t, C19), 43.97 (s, C20), 31.19 (t,
C21), 38.33 (t, C22), 27.75 (q, C23), 16.30 (q, C24), 15.16 (q, C25),
15.95 (q, C26), 20.78 (q, C27), 26.83 (q, C28), 28.59 (q, C29), 177.44
(s, C30), 51.36 (q, C31), 170.70 (s, C32), 21.09 (q, C33); HRMS: m/z
calcd for C33H52O5: 528.7630; found: 528.3815.
Methyl 3b-acetoxy-12-oxo-18bH-olean-9(11)-en-30-oate (6):
Compound 6 was synthesized according to a known method.
[44]
Briefly, a solution of bromine (0.5 mL, 9.8 mmol) in glacial acetic
acid (50 mL) was added dropwise at 808C to a stirred solution of 5
(4.0 g, 7.6 mmol) in glacial acetic acid (150 mL) over 1 h. The reac-
tion mixture was stirred for a further 1 hour at 808C, cooled to
room temperature, diluted with water (1.5 L) and filtered. The solid
was washed with water, dried, and subjected to flash column chro-
matography (silica gel, chloroform) to give a solid 6 (yield=3.0 g,
75%). This material was used for the next reaction without further
purification. An analytically pure sample was obtained by recrystal-
lization from a mixture chloroform/methanol. M.p. 2988C;
1H NMR
(CDCl3): d=0.84 (m; H
16e), 0.85 (s, 3H; C24-H3), 0.86 (s, 6H; C23-H3,
C28-H3), 0.91 (s, 3H; C27-H3), 0.94 (dm,
3J(H
5a,H
6a)=10 Hz; H
5a), 1.01
(dm,
2J(H
15e,H
15a)=13.2 Hz; H
15e), 1.07 (s, 3H; C29-H3), 1.16 (s, 3H;
C25-H3), 1.20 (dd,
2J(H
19a,H
19e)=13.3,
3J(H
19a,H
18)=13.3 Hz; H
19a),
1.16–1.27 (m, 2H; H
21a,H
22e), 1.32 (s, 3H; C26-H3), 1.35–1.44 (m, 2H;
H
1a,H
7e), 1.46 (ddd,
2J(H
22a,H
22e)=14.0,
3J(H
22a,H
21a)=14.0,
3J(H
22a,H
21e)=4.2 Hz; H
22a), 1.55–1.73 (m, 5H; 2H
6,H
7a,2 H
2), 1.77
(m; H
15a), 1.83 (m; H
16a), 1.90 (m, 2H; H
1e,H
21e), 1.93 (dm,
3J(H
18,H
19a)=13.3; H
18), 2.00 (s, 3H; C33-H3), 2.16 (ddd,
2J(H
19e,H
19a)=
13.3,
3J(H
19e,H
18)=3.4,
4J(H
19e,H
21e)=2.8 Hz; H
19e), 2.92 (d,
3J(H
13,H
18)=4.7 Hz; H
13), 3.69 (s, 3H; OC31-H3), 4.43 (dd,
3J(H
3a,H
2a)=
11.7,
3J(H
3a,H
2e)=4.5 Hz; H
3a), 5.72 (s; H
11);
13C NMR (CDCl3): d=
35.86 (t, C1), 23.66 (t, C2), 79.49 (d, C3), 37.95 (s, C4), 50.08 (d, C5),
17.67 (t, C6), 32.66 (t, C7), 45.29 (s, C8), 177.61 (s, C9), 39.59 (s,
C10), 122.89 (d, C11), 201.14 (s, C12), 47.70 (d, C13), 41.61 (s, C14),
26.03 (t, C15), 26.03 (t, C16), 31.87 (t, C17), 37.81 (d, C18), 33.69 (t,
C19), 43.88 (s, C20), 31.10 (t, C21), 38.13 (t, C22), 27.77 (q, C23),
16.46 (q, C24), 23.79 (q, C25), 23.85 (q, C26), 21.84 (q, C27), 26.90
(q, C28), 28.45 (q, C29), 177.22 (s, C30), 51.32 (q, C31), 170.59 (s,
C32), 21.01 (q, C33); HRMS: m/z calcd for C33H50O5: 526.7471;
found: 526.3658.
Methyl 3b-hydroxy-12-oxo-18bH-olean-9(11)-en-30-oate (7): A
mixture of 6 (6.2 g, 11.8 mmol) and KOH (41 g, 732 mmol) in meth-
anol (400 mL) was heated under reflux for 1.5 h. The resulting solu-
tion was cooled to room temperature, concentrated in vacuo, and
10% aqueous hydrochloric acid solution was added. The mixture
was extracted with chloroform/ethyl acetate (1:4, 3 75 mL). The
combined organic layers were washed with saturated sodium hy-
drogen carbonate solution (3 50 mL) and brine (3 50 mL), and
dried over magnesium sulfate. The solvent was removed to give a
solid 7 (yield=5.13 g, 90%). This material was used for the next re-
action without further purification. An analytically pure sample was
obtained by recrystallization from a mixture chloroform/methanol.
M.p. 202–2038C;
1H NMR: d=0.80 (s, 3H; C24-H3), 0.89 (s, 3H; C28-
H3), 0.94 (s, 3H; C27-H3), 1.01 (s, 3H; C23-H3), 1.08 (s, 3H; C29-H3),
1.16 (s, 3H; C25-H3), 1.35 (s, 3H; C26-H3), 0.83–0.91 (m, 2H; H
5a,
H
16e), 1.04 (dm,
2J(H
15e,H
15a)=12.8 Hz; H
15e), 1.23 (dd,
2J(H
19a,H
19e)=
13.2,
3J(H
19a,H
18)=13.2 Hz; H
19a), 1.18–1.25 (m; H
21a), 1.27 (dm,
2J(H
22e,H
22a)=14.0 Hz; H
22e), 1.31 (m; H
1a), 1.44 (dm,
2J(H
7e,H
7a)=
9.8 Hz; H
7e), 1.49 (ddd,
2J(H
22a,H
22e)=14.0,
3J(H
22a,H
21a)=14.0,
3J(H
22a,H
21e)=4.2 Hz; H
22a), 1.55–1.76 (m, 5H; 2H
6,H
7a,2 H
2), 1.80
(m, H
15a), 1.85 (m; H
16a), 1.89–2.00 (m, 3H; H
1e,H
21e,H
18), 2.19 (ddd,
2J(H19
e,19
a)=13.2,
3J(H
19e,H
18)=3.2,
4J(H
19e,H
21e)=2.7 Hz; H
19e), 2.95
(d,
3J(H
13,H
18) 4.7 Hz; H
13), 3.18 (dd
3J(H
3a,H
2a)=11.7,
3J(H
3a,H
2e)=
4.4 Hz; H
3a), 3.71 (s, 3H; OC31-H3), 5.76 (s, H
11);
13C NMR (CDCl3):
d=36.22 (t, C1), 27.38 (t, C2), 77.83 (d, C3), 39.11 (s, C4), 50.06 (d,
C5), 17.87 (t, C6), 32.79 (t, C7), 45.39 (s, C8), 178.10 (s, C9), 39.81 (s,
C10), 122.85 (d, C11), 201.36 (s, C12), 47.76 (d, C13), 41.70 (s, C14),
26.14 (t, C15), 26.12 (t, C16), 31.95 (s, C17), 37.88 (d, C18), 33.79 (t,
C19), 43.95 (s, C20), 31.17 (t, C21), 38.21 (t, C22), 27.96 (q, C23),
15.44 (q, C24), 23.81 (q, C25), 23.87 (q, C26), 21.99 (q, C27), 26.96
(q, C28), 28.52 (q, C29), 177.33 (s, C30), 51.43 (q, C31); HRMS: m/z
calcd for C31H48O4: 484.7104; found: 484.3553.
Methyl 3,12-Dioxo-18bH-olean-9(11)-en-30-oate (8): Jones re-
agent (5 mL), prepared from Na2Cr2O7·2H2O in dilute sulfuric acid
(33%)
[45] was added dropwise to a solution of 7 (5.13 g) in acetone
(500 mL) at 08C over 30 min till the brown color persisted. The
mixture was stirred for further 2.5 h at room temperature, and eth-
anol (10 mL) was added. The resulting mixture was concentrated in
a vacuum (~100 mL), and water (1 L) was added. The solid was fil-
tered and dried. The ketone 8 was purified by column chromatog-
raphy (neutral alumina, chloroform) (yield=4.7 g, 94%). This mate-
rial was used for the next reaction without further purification. An
analytically pure sample was obtained by recrystallization from a
mixture chloroform/methanol. M.p. 189–1928C;
1H NMR (CDCl3):
d=0.88 (s, 3H; C28-H3), 0.94 (s, 3H; C27-H3), 1.05 (s, 3H; C24-H3),
1.07 (s, 3H; C29-H3), 1.08 (s, 3H; C23-H3), 1.27 (s, 3H; C25-H3), 1.38
(s, 3H; C26-H3), 0.89 (m, H
16e), 1.06 (m, H
15e), 1.21 (dd,
2J(H
19a,H
19e)=
13.3,
3J(H
19a,H
18)=13.3 Hz; H
19a), 1.17–1.29 (m, 2H; H
21a,H
22e), 1.43–
1.50 (m, 2H; H
5a,H
7), 1.48 (ddd,
2J(H
22a,H
22e)=14.0,
3J(H
22a,H
21a)=
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3J(H
22a,H
21e)=4.3 Hz; H
22a), 1.60–1.72 (m, 3H; 2H
6,H
7’), 1.75 (m,
H
1a), 1.80 (m; H
15a), 1.85 (m, H
16a), 1.92 (m, H
21e), 1.96 (ddd,
3J(H
18,H
19a)=13.3,
3J(H
18,H
13)=4.7,
3J(H
18,H
19e)=3.2 Hz; H
18), 2.16 (m,
H
1e), 2.17 (ddd,
2J(H
19e,H
19a)=13.3,
3J(H
19e,H
18)=3.2,
4J(H
19e,H
21e)=
2.8 Hz; H
19e), 2.44 (ddd,
2J(H
2e,H
2a)=15.8,
3J(H
2e,H
1a)=7.2,
3J(H
2e,H
1e)=3.8 Hz; H
2e), 2.60 (ddd,
2J(H
2a,H
2e)=15.8,
3J(H
2a,H
1a)=
11.5,
3J(H
2a,H
1e)=7.3 Hz; H
2a), 2.98 (d,
3J(H
13,H
18)=4.7 Hz; H
13), 3.70
(s, OC31-H3), 5.78 C(H
11);
13C NMR (CDCl3): d=36.80 (t, C1), 33.97 (t,
C2), 215.57 (s, C3), 47.35 (s, C4), 50.73 (d, C5), 18.97 (t, C6), 31.90 (t,
C7), 45.46 (s, C8), 176.36 (s, C9), 39.23 (s, C10), 124.10 (d, C11),
200.78 (s, C12), 47.86 (d, C13), 41.78 (s, C14), 26.13 (t, C15), 26.11 (t,
C16), 31.90 (s, C17), 37.82 (d, C18), 33.76 (t, C19), 43.90 (s, C20),
31.12 (t, C21), 38.14 (t, C22), 26.10 (q, C23), 21.25 (q, C24), 23.69 (q,
C25), 23.75 (q, C26), 21.81 (q, C27), 26.94 (q, C28), 28.45 (q, C29),
177.19 (s, C30), 51.37 (q, C31); HRMS: m/z calcd for C31H46O4:
484.6945; found: 484.3396.
Methyl 2-hydroxymethylene-3,12-dioxo-18bH-olean-9(11)-en-30-
oate (9): Ethyl formate (3.75 mL, 39.5 mmol) and sodium methylate
(2.1 g, 38.9 mmol) were added to a solution of ketone 8 (4.5 g,
9.3 mmol) in dry benzene (50 mL). The mixture was stirred at room
temperature for 2 h. The reaction mixture was diluted with a mix-
ture of chloroform/diethyl ether (1:3, 100 mL), and 5% HCl was
added to achieve pH<7. The organic layer was separated, and the
aqueous layer was extracted with chloroform/diethyl ether (1:3, 3 
50 mL). The combined organic layers were washed with saturated
sodium hydrogen carbonate solution (3 50 mL), and brine (3 
50 mL), and dried over magnesium sulfate. The solvent was re-
moved to give an amorphous solid 9 (yield=4.5 g, 95%). This ma-
terial was used for the next reaction without further purification.
An analytically pure sample was obtained by flash column chroma-
tography (silica gel; hexane/ethyl acetate (9:1) followed by
hexane/ethyl acetate (3:1)).
1H NMR (CDCl3): d=0.90 (s, 3H; C28-
H3), 0.96 (s, 3H; C27-H3), 1.09 (s, 3H; C29-H3), 1.13 (s, 3H; C24-H3),
1.15 (s, 3H; C25-H3), 1.20 (s, 3H; C23-H3), 1.38 (s, 3H; C26-H3), 0.91
(m, H
16e), 1.07 (m, H
15e), 1.23 (dd,
2J(H
19a,H
19e)=13.3,
3J(H
19a,H
18)=
13.3 Hz; H
19a), 1.18–1.31 (m, 3H; H
21a,H
22e,H
5a), 1.49 (ddd,
2J(H
22a,H
22e)=14.0,
3J(H
22a,H
21a)=14.0,
3J(H
22a,H
21e)=4.1 Hz; H
22a),
1.47–1.53 (m, H
7), 1.59–1.67 (m, 3H; 2H
6,H
7’), 1.82 (m, H
15a), 1.86
(m, H
16a), 1.94 (dddd
2J(H
21e,H
21a)=13.3,
3J(H
21e,H
22a)=4.1,
3J(H
21e,H
22e)=3.4,
4J(H
21e,H
19e)=2.7 Hz; H
21e), 1.99 (ddd,
3J(H
18,H
19a)=
13.3,
3J(H
18,H
13)=4.6,
3J(H
18,H
19e)=3.3 Hz; H
18), 2.21 (ddd,
2J(H
19e,H
19a)=13.3,
3J(H
19e,H
18)=3.3,
4J(H
19e,H
21e)=2.7 Hz; H
19e), 2.26
(d,
2J(H
1,H
1’)=14.5 Hz; H
1) and 2.58 (d,
2J(H
1’,H
1)=14.5 Hz; H
1’)—AB-
system, 3.02 (d,
3J(H
13,H
18)=4.6 Hz; H
13), 3.71 (s, 3H; OC31-H3), 5.90
(s, H
11), 8.70 (d,
3J(H
32
,OH)=2.4 Hz; H
32), 14.81 (d,
3J (OH,H
32)=
2.4 Hz; OH);
13C NMR (CDCl3): d=36.85 (t, C1), 104.80 (s, C2),
188.08 (s, C3), 40.32 (s, C4), 48.07 (d, C5), 18.80 (t, C6), 31.25 (t, C7),
45.55 (s, C8), 175.36 (s, C9), 38.89 (s, C10), 124.37 (d, C11), 200.73 (s,
C12), 47.86 (d, C13), 41.80 (s, C14), 26.22 (t, C15), 26.14 (t, C16),
31.93 (s, C17), 37.82 (d, C18), 33.74 (t, C19), 43.93 (s, C20), 31.14 (t,
C21), 38.18 (t, C22), 28.14 (q, C23), 20.65 (q, C24), 23.36 (q, C25),
23.23 (q, C26), 21.82 (q, C27), 26.96 (q, C28), 28.48 (q, C29), 177.22
(s, C30), 51.42 (q, C31), 189.65 (d, C32); HRMS: m/z calcd for
C32H46O5: 510.7046; found: 510.3345.
Methyl 12-oxoisoxazolo[4,5-b]-18bH-olean-9(11)-en-30-oate (10):
Hydroxylamine hydrochloride (6.0 g, 86.0 mmol) was added to a
solution of 9 (4.4 g, 8.6 mmol) in ethanol (120 mL) and water
(12 mL). The mixture was heated under reflux for 2 h, cooled to
room temperature, concentrated in vacuo, and water (100 mL) was
added. The mixture was extracted with ethyl acetate (3 70 mL).
The combined organic layers were washed with water (3 50 mL),
brine (3 50 mL) and dried over magnesium sulfate. The solvent
was evaporated and the solid was purified by column chromatog-
raphy (silica gel; hexane/ethyl acetate (3:1)) to give 10 (yield=
3.2 g, 73%).
1H NMR (CDCl3): d=0.91 (s, 3H; C28-H3), 0.98 (s, 3H;
C27-H3), 1.10 (s, 3H; C29-H3), 1.15 (s, 3H; C25-H3), 1.24 (s, 3H; C24-
H3), 1.32 (s, 3H; C23-H3), 1.40 (s, 3H; C26-H3), 0.91 (m, H
16e), 1.06–
1.11 (m, H
15e), 1.24 (dd,
2J(H
19a,H
19e)=13.2,
3J(H
19a,H
18)=13.2 Hz;
H
19a), 1.19–1.34 (m, 2H; H
21a,H
22e), 1.44–1.57 (m, 3H; H
5a,H
22a,H
7),
1.64–1.79 (m, 3H; 2H
6,H
7’), 1.84 (m, H
15a), 1.88 (m, H
16a), 1.95
(dddd,
2J(H
21e,H
21a)=13.3,
3J(H
21e,H
22a)=4.2,
3J(H
21e,H
22e)=3.2,
4J(H
21e,H
19e)=2.7 Hz; H
21e), 2.00 (ddd
3J(H
18,H
19a)=13.2,
3J(H
18,H
13)=
4.6,
3J(H
18,H
19e)=3.2 Hz; H
18), 2.21 (ddd,
2J(H
19e,H
19a)=13.2,
3J(H
19e,H
18)=3.2,
4J(H
19e,H
21e)=2.7 Hz; H
19e), 2.38 (d,
2J(H
1,H
1’)=
15.0 Hz; H
1) and 2.75 (d,
2J(H
1’,H
1)=15.0 Hz; H
1’)—AB system, 3.04
(d,
3J(H
13,H
18)=4.6 Hz; H
13), 3.73 (s, 3H; OC31-H3), 5.89 (s, H
11), 8.04
(s, H
32);
13C NMR (CDCl3): d=33.42 (t, C1), 108.38 (s, C2), 171.94 (s,
C3), 35.01 (s, C4), 49.53 (d, C5), 18.16 (t, C6), 31.24 (t, C7), 45.75 (s,
C8), 175.87 (c, C9), 41.09 (s, C10), 124.65 (d, C11), 200.77 (s, C12),
47.90 (d, C13), 41.79 (s, C14), 26.27 (t, C15), 26.13 (t, C16), 31.95 (s,
C17), 37.85 (d, C18), 33.79 (t, C19), 43.95 (s, C20), 31.16 (t, C21),
38.18 (t, C22), 28.65 (q, C23), 21.26 (q, C24), 24.52 (q, C25), 23.28 (q,
C26), 21.87 (q, C27), 26.99 (q, C28), 28.51 (q, C29), 177.26 (s, C30),
51.47 (q, C31), 150.06 (d, C32); HRMS: m/z calcd for C32H45NO4:
507.7040; found: 507.3349.
The mixture of tautomers (11): Sodium methylate (11 g,
204 mmol) was added at 08C to a solution of isoxazole 10 (3.0 g,
5.9 mmol) in methanol (85 mL) and diethyl ether (170 mL). The
mixture was stirred at room temperature for 1 h. The resulting mix-
ture was diluted with a mixture of chloroform/diethyl ether (1:3;
100 mL), and 5% HCl was added to achieve pH<7. The organic
layer was separated, and the aqueous layer was extracted with
chloroform/diethyl ether (1:3; 3 50 mL). The combined organic
layers were washed with saturated sodium hydrogen carbonate so-
lution (3 50 mL) and brine (3 50 mL), and dried over magnesium
sulfate. The solvent was removed to give a mixture of tautomers
11 (yield=3.0 g, 100%). This material was used for the next reac-
tion without further purification. HRMS: m/z calcd for C32H45NO4:
507.7040; found: 507.3349.
Methyl 2-cyano-3,12-dioxo-18bH-olean-9(11),1(2)-dien-30-oate
(12): Mixture 11 (2.8 g, 5.5 mmol) and 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) (1.5 g, 6.5 mmol) in dry benzene (160 mL)
were heated under reflux for 4 h. Insoluble matter was removed by
filtration, and the filtrate was evaporated in a vacuum to give a
solid. The solid was subjected to flash column chromatography
(silica gel; benzene followed by benzene/acetone (10:1)) to give
crude 12. The crude product was purified by recrystallization from
methanol/chloroform to give crystals 12 (yield 1.7 g, 61%). M.
p. 247–2498C;
1H NMR (CDCl3): d=0.90 (s, 3H; C28-H3), 0.96 (s, 3H;
C27-H3), 1.09 (s, 3H; C29-H3), 1.14 (s, 3H; C24-H3), 1.22 (s, 3H; C23-
H3), 1.44 C (s, 3H; C26-H3), 1.47 (s, 3H; C25-H3), 0.93 (dm,
2J(H
16e,H
16a)=13.3 Hz; H
16e), 1.08 (m, H
15e), 1.20 (dd,
2J(H
19a,H
19e)=
13.2,
3J(H
19a,H
18)=13.2 Hz; H
19a), 1.18–1.32 (m, 2H; H
21a,H
22e), 1.48
(ddd,
2J(H
22a,H
22e)=14.0,
3J(H
22a,H
21a)=14.0,
3J(H
22a,H
21e)=4.2 Hz;
H
22a), 1.55 (dm,
2J(H
7e,H
7a)=13.5 Hz; H
7e), 1.67–1.79 (m, 4H; H
5a,
2H
6,H
7a), 1.82 (m, H
15a), 1.87 (m, H
16a), 1.94 (dddd,
2J(H
21e,H
21a)=
13.3,
3J(H
21a,H
22a)=4.2,
3J(H
21e,H
22e)=3.2,
4J(H
21e,H
19e)=2.8 Hz; H
21e),
2.02 (ddd,
3J(H
18,H
19a)=13.2,
3J(H
18,H
13)=4.7,
3J(H
18,
19e)=3.2 Hz; H
18),
2.17 (ddd,
2J(H
19e,H
19a)=13.2,
3J(H
19e,H
18)=3.2,
4J(H
19e,H
21e)=2.8 Hz;
H
19e), 3.02 (d,
3J(H
13,H
18)=4.7 Hz; H
13), 3.72 (s, 3H; OC31-H3), 5.97 (s,
H
11), 8.01 (s, H
1);
13C NMR (CDCl3): d=165.65 (d, C1), 114.46 (s, C2),
196.42 (s, C3), 44.86 (s, C4), 47.57 (d, C5), 18.12 (t, C6), 31.58 (t, C7),
45.82 (s, C8), 168.18 (s, C9), 42.36 (s, C10), 124.17 (d, C11), 199.52 (s,
C12), 48.04 (d, C13), 42.10 (s, C14), 26.03 (t, C15), 26.00 (t, C16),
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E. B. Logashenko, M. A. Zenkova, et al.31.88 (s, C17), 37.75 (d, C18), 33.61 (t, C19), 43.91 (s, C20), 31.11 (t,
C21), 38.14 (t, C22), 26.88 (q, C23), 21.40 (q, C24), 26.61 (q, C25),
24.77 (q, C26), 21.81 (q, C27), 26.96 (q, C28), 28.46 (q, C29), 177.13
(s, C30), 51.48 (q, C31), 114.22 (s, C32); HRMS: m/z calcd for
C32H43NO4: 505.6881; found: 505.3192.
Cell culture and glycyrrhetinic acids derivatives: Human KB-3-1
epidermoid carcinoma cell line, HeLa cervical epithelioid carcinoma
cell line, MCF-7 breast adenocarcinoma cell line, SKNMC neuroblas-
toma cell line (Russian Cell Culture Collection, St. Petersburg), KB-8-
5 multidrug resistant cancer cell line (kindly provided by Professor
M. Gottesman (NIH, USA)), were cultured in DMEM supplemented
with 10% (v/v) heat-inactivated fetal bovine serum, penicillin
(100 U mL
1; ICN Biomedicals, Inc), streptomycin (100 mgmL
1) and
amphotericin (250 mgmL
1). Cells were maintained in a humidified
atmosphere (5% CO2,3 7 8C). The KB-8-5 cell line was incubated in
the additional presence of vinblastine (300 nmolL
1).
Glycyrrhetinic acids derivatives were dissolved in DMSO
(10 mmolL
1), and stock solution were stored at 208C.
After treatments, both floating and adherent scraped cells were
collected by centrifugation, and used for further analysis.
Cell viability analysis by MTT assay: Cancer cells, growing in log
phase, were seeded in triplicate 96-well plates at a density of 5 
10
3 cells per well for HeLa cells, 7 10
3 for KB-3-1, KB-8-5 and MCF-
7 cells, and 30 10
3 for SKNMC cells. The plates were incubated at
378C in humidified 5% CO2 atmosphere. Cells were allowed to
adhere to the surface for 24 h, then treated with varying doses of
the compounds for 24 h. Aliquots of [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] (MTT) solution (10 mL, 5 mgmL
1)
were added to each well, and the incubation was continued for an
additional 3 h. The dark blue formazan crystals (formed within
healthy cells) were solubilized with DMSO, and the absorbance
was measured at 570 nm in a Multiscan RC plate reader (Thermo
LabSystems , Finland). The IC50 was determined as the compound
concentration required to decrease the A570 to 50% of the control
(no compound, DMSO), and was determined by interpolation from
dose-response curves.
Analysis of antioxidant effect on the cytotoxicity of compound
12: KB-3-1 cells growing in the log phase were seeded in triplicate
in 96-well plates (7 10
3 cells per well). The plates were incubated
at 378C in a humidified 5% CO2 atmosphere. Cells were allowed to
adhere to the surface for 24 h, then treated with GSH (1, 5, 15 or
45 mm) or with ascorbic acid (1, 3 or 5 mm), both alone and in
combination with 12 (1 mm). Cells were incubated with the com-
pounds for 24 h and cell viability was analyzed by the MTTassay as
described above.
Morphological observation of nuclear change: KB-3-1 cells were
seeded into 24-well plates (10
5 cells per well) containing glass
cover slips. Cells were allowed to adhere to the surface for 24 h.
Cells were treated with 12 (1 mm) or with DMSO (0.1% (v/v)) for 6,
18 or 24 h at 378C in a humidified 5% CO2 atmosphere. After incu-
bation, cells were fixed with 4% formaldehyde for 15 min, and
then stained for 30 min with Hoechst 33258 (200 ngmL
1). Cells
were analyzed for the presence of fragmented nuclei and con-
densed chromatin by fluorescent microscopy.
Apoptosis detection by Annexin V staining: Log-phase KB-3-1
cells in six-well plates (5 10
5 cells per well) were treated with 12
(0.3 mm or 1 mm) or with DMSO (0.1% (v/v)) for 4, 18 or 24 h. The
cells were stained with Annexin V-FITC and propidium iodide by
using the ApopNexin-FITC apoptosis detection kit (Chemicon Milli-
pore) according to the manufacturer’s instructions. Briefly, cells
were collected by scraping, washed twice with cold PBS, and cen-
trifuged (400g, 5 min). Cells were resuspended in binding buffer
(1 mL) at a concentration of 1 10
6 cells per mL, then a sample
(200 mL) was transferred to a 5 mL culture tube, and Annexin V-
FITC (3 mL) and 100 PI (2 mL) were added. Cells were incubated for
15 min at room temperature in the dark. Finally, binding buffer
(300 mL) was added to each tube, and the quantity of apoptotic
cells in samples was analyzed by flow cytometry (FC500, Beckman
Coulter, USA). For each sample, 10000 ungated events were ac-
quired. Annexin V
+/PI
 cells represented early apoptotic popula-
tions. Annexin V
+/PI
+ cells represented either late apoptotic or
secondary necrotic populations.
Mitochondria depolarization analysis: Mitochondria involvement
in apoptosis was measured by the mitochondrial depolarization
that occurs early during the onset of apoptosis. KB-3-1 cells were
treated with 1( 1 mm), 12 (1 mm) or DMSO (0.1% (v/v)) for 6 h, and
loss of mitochondrial potential was determined by using the mito-
chondrial potential sensor JC-1 (Molecular Probes, Invitrogen).
Flow cytometry assay: Cells were incubated for the appropriate
time with the compounds, then collected, incubated in complete
media in the dark with JC-1 (5 mgmL
1)a t3 7 8C for 15 min, and
washed with PBS. At the end of the incubation period the cells
were washed twice with cold PBS, and resuspended in PBS
(400 mL). J-aggregate and J-monomer fluorescence were recorded
in the channesl 2 (FL2) and 1 (FL1), respectively, of an FC500 flow
cytometer. Necrotic fragments were electronically gated out, on
the basis of morphological characteristics on the forward light scat-
ter versus side light scatter dot plot.
Fluorescent microscopy assay: Cells were plated into 24-well plates
(10
5 cells per well) containing glass cover slips, and allowed to
adhere to the surface for 24 h. Cells were incubated for the appro-
priate time with the compounds. After incubation the cell culture
media was removed and replaced with JC-1 reagent (5 mm) diluted
in PBS. Cells were incubated at 378Ci na5 %C O 2 incubator for
15 min, and analyzed by fluorescence microscopy.
Cytofluorimetric analysis of DNA content: Exponentially growing
KB-3-1 cells in 6-well plates (5 10
5 cells per well) were treated
with 12 (0.3 mm,o r1mm) or DMSO (0.1% (v/v)) for 18 h. After incu-
bation, the cells were collected by centrifugation (400 g, 10 min),
fixed with ice-cold 70% ethanol for at least 1 h at 48C and treated
with RNase A from bovine pancreas (1 mgmL
1; Sigma) for 30 min
at 378C. PI (50 mgmL
1) was then added to the solution and the
DNA content was quantitated by a flow cytometry. Cells in sub-G1
phase were considered apoptotic.
Analysis of caspase activation: After treatment of KB-3-1 cells
with 1 (0.3 mm,1mm), or 12 (0.3 mm,1mm), or DMSO (0.1% (v/v))
for 18 h, caspase activation was assayed by using the CaspACE
FITC-VAD-FMK in situ marker (Promega).
Flow cytometry assay: Cells were incubated for the appropriate
time in the presence of the compounds, collected, suspended in
PBS (0.5 mL), and FITC-VAD-FMK (1 mL, 5 mm) was added. The cells
were gently mixed and incubated for 20 min at RT in the dark.
Cells were washed twice with PBS, and the pellets resuspended in
PBS (0.5 mL). Flow cytometry was conducted within 10 min.
Fluorescent microscopy assay: Cells were seeded (10
5 cells per well)
into 24-well plates containing glass cover slips, and allowed to
adhere to the surface for 24 h. After incubation for the appropriate
time with the compounds, the cell culture medium was removed
and replaced with JC-1 reagent (5 mm) diluted in PBS. Cells were in-
cubated at 378Ci na5 %C O 2 incubator for 15 min. The cells were
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